Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

by: Bernhard Berger, Claus Belka

Radiation Oncology, Vol. 3, No. 1. (2008)

View FullText article

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

Find related articles with these CiteULike tags

cetuximab, skinreactions

Abstract

The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population, several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy.

@article{citeulike:2298515, abstract = {The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population, several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy.}, author = {Berger, Bernhard and Belka, Claus }, citeulike-article-id = {2298515}, doi = {http://dx.doi.org/10.1186/1748-717X-3-5}, journal = {Radiation Oncology}, keywords = {cetuximab, skinreactions}, number = {1}, posted-at = {2008-01-28 18:18:00}, priority = {2}, title = {Severe skin reaction secondary to concomitant radiotherapy plus cetuximab}, url = {http://dx.doi.org/10.1186/1748-717X-3-5}, volume = {3}, year = {2008} }

RIS record

TY - JOUR ID - citeulike:2298515 L3 - citeulike-article-id:2298515 TI - Severe skin reaction secondary to concomitant radiotherapy plus cetuximab JF - Radiation Oncology VL - 3 IS - 1 N2 - The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population, several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy. KW - cetuximab KW - skinreactions AU - Berger, Bernhard AU - Belka, Claus PY - 2008/// UR - http://dx.doi.org/10.1186/1748-717X-3-5 ER -

RIS BibTeX